Axelrod H R, Liao M J, Kuchler M, Testa D
CYTOGEN Corporation, Princeton, New Jersey 08540.
Biotechnol Ther. 1992;3(1-2):35-49.
Human leukocyte-derived interferon alfa-n3 (Alferon N Injection) is purified to very high specific activity over a murine immunoaffinity column specific for human interferon alpha. Trace amounts of murine immunoglobulin copurify with the interferon alfa-n3. Three populations of individuals were studied for the development of human anto-murine antibodies (HAMA), that is, normal donors, Condylomata acuminata patients receiving interferon alfa-n3, and Condylomata acuminata patients receiving placebo. High and variable endogenous levels of HAMA were observed in all three populations. The same relative increase in HAMA was seen in the placebo as in the interferon alfa-n3 treatment groups. The data demonstrate that intralesional injection of the interferon alfa-n3 did not induce the development of HAMA.
人白细胞源性干扰素α-n3（Alferon N注射剂）在针对人干扰素α的鼠免疫亲和柱上纯化至非常高的比活性。痕量的鼠免疫球蛋白与干扰素α-n3共纯化。研究了三组人群中人抗鼠抗体（HAMA）的产生情况，即正常供体、接受干扰素α-n3治疗的尖锐湿疣患者以及接受安慰剂的尖锐湿疣患者。在所有三组人群中均观察到高水平且变化的内源性HAMA。安慰剂组和干扰素α-n3治疗组中HAMA的相对增加相同。数据表明，病灶内注射干扰素α-n3不会诱导HAMA的产生。
